Serum levels of soluble form of receptor for advanced glycation end products in type 2 diabetes mellitus patients with restenosis after intracoronary drug eluting stent implantation

Abstract

Aim. To assess blood concentrations of soluble receptor for advanced glycation end products (sRAGE) involvement in restenosis development after drug-eluting stent (DES) implantation in patients with stable angina pectoris (AP) and type 2 diabetes mellitus (DM).
Material and Methods. The study comprised 126 male and female patients, including 55 patients with type 2 diabetes mellitus, with stable AP who underwent elective percutaneous coronary angioplasty with DES and follow-up coronary angiography within 6–12 months thereafter. According to the follow-up angiograms, the patients were assigned to the group with restenosis or group without restenosis. Both groups of patients were compared in regard to the level of sRAGE at the time of follow-up angiography.
Results. Serum levels of sRAGE in patients with restenosis were lower compared with those patients without restenosis. This difference was related to the difference in the levels of sRAGE in patients with and without restenosis who had type 2 DM. Serum levels [median (25th; 75th percentile)] of sRAGE in DM patients with restenosis were lower compared with those DM patients without restenosis [1,08 (0,91; 1,19) vs. 1,27 (0,99; 1,58) ng/ml, p<0,001]. Serum levels of sRAGE in non-DM patients did not differ significantly in those patients with or without restenosis.
Conclusion. Our data suggest that serum levels of sRAGE are associated with restenosis occurrence in type 2 DM patients after DES implantation for stable AP.